Both these cases utilized cell therapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) from donors with a homozygous CCR5 delta32 mutation (CCR5Δ32) for an associated hematological malignancy. Here, CCR5 is linked to hematologic disorder.